All Oncology News

Grzegorz S. Nowakowski, MD, discusses the accelerated approval of epcoritamab in follicular lymphoma, touching on key trial data and remaining unmet needs.

The HHS competition evaluated the effectiveness of Ochsner Connected MOM in increasing blood pressure monitoring during pregnancy and the postpartum period.

As the lung cancer paradigm continues to advance, increasingly effective therapies are under development for previously underserved disease subtypes.

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.

Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.

Frontline eftilagimod alpha plus pembrolizumab was safe and elicited responses in patients with PD-L1–negative head and neck squamous cell carcinoma.

Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.

Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.

Aaron Gerds, MD, discusses progression data for patients with low- or intermediate-1–risk myelofibrosis in the MOST trial.

Research team shares new data on how XPO1 blockade may boost immune-based treatments.

SLS009 has been granted orphan drug designation by the EMA for the treatment of patients with acute myeloid leukemia.

Recent studies of novel mTOR inhibitors in combination with various agents have shown how these combinations may be used for patients with solid tumors.

A 100-mg dose of tarlatamab was safe and showed particularly robust activity in patients with DLL3-positive neuroendocrine prostate cancer.

The HER2-directed ADC FS-1502 was well tolerated and generated early signals of antitumor activity in patients with HER2-expressing breast cancer.

Mikkael A. Sekeres, MD, discusses the FDA approval of imetelstat for patients with low- to intermediate-1–risk MDS, highlighting data from a subanalysis.

Tycel Phillips, MD, highlights key takeaways in NHL, MDS, and myelofibrosis from an OncLive State of the Science Summit on hematology.

Jeffrey M. Farma, MD, FACS, has been appointed Chair of Surgery at Fox Chase Cancer Center.

Paxalisib improved OS over SOC in patients with newly diagnosed glioblastoma and unmethylated MGMT promotor status.

Curium has submitted an NDA to the FDA for its formulation of lutetium Lu 177 dotatate for SSTR-positive gastroenteropancreatic neuroendocrine tumors.

Up to 12 months of treatment with SGX301 produced lesion responses in patients with early-stage cutaneous T-cell lymphoma.

Panelists from an OncLive Peer Exchange detail updated data in the hormone receptor–positive HER2– breast cancer treatment landscape.

Don Dizon, MD, discusses updated findings from the BrUOG 354 trial and the future of immunotherapy for patients with ovarian cancers.

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab for the treatment of cutaneous squamous cell carcinoma.

GLPG5101 produced high CRs in patients with relapsed/refractory non-Hodgkin lymphoma, indicating the feasibility of decentralized CAR T manufacturing.

The FDA has granted fast track designation to OBX-115 for advanced melanoma that is refractory to or relapsed after immune checkpoint inhibitors.

Botensilimab plus balstilimab generated responses in relapsed/refractory microsatellite stable metastatic colorectal cancer.

Noa Biran, MD, discusses key data from clinical trials in multiple myeloma presented at the 2024 ASCO Annual Meeting.

The BLA seeking approval for remestemcel-L for children with steroid-refractory acute graft-vs-host-disease has been resubmitted to the FDA.

Elevar Therapeutics plans to resubmit a new drug application for rivoceranib plus camrelizumab for first-line unresectable hepatocellular carcinoma.

Maurie Markman, MD, details the concept of hope during cancer diagnoses, touching on the announcement from Catherine, Princess of Wales.